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Summary
Background: Complex regional pain syndrome
(CRPS) following stroke aggravates morbidity.
CRPS is categorized as CRPSI when no clear nerve
injury is defined, and CRPSII when associated with
clear nerve injury.
Aim: To compare the effect of prednisolone with
that of piroxicam in patients with CRPSI following
stroke.
Design: Randomized controlled trial.
Methods: Patients with CRPSI fulfilling the inclusion
criteria (n¼ 60) underwent a detailed neurological
examination, cranial CT scan, radiograph of chest
and shoulder joint, blood counts and serum chem-
istry. Severity of stroke was assessed by the Canadian
Neurological Scale (CNS), CRPS by scoring sensory,
autonomic andmotor symptoms, and activity of daily
living by Barthel index (BI) score. Patients were
randomly assigned prednisolone 40mg or piroxicam
20mg daily, and outcome was assessed at 1 month
on the basis of CRPS and BI score.
Results:Mean patient age was 56 years and 20 were
female. Baseline clinical and radiological param-
eters were comparable between the two groups.
In the prednisolone group, 83.3% patients showed
significant improvement, compared to 16.7% in the
piroxicam group. The mean change in CRPS score
in prednisolone group was 6.47 (95%CI 4.37–7.36),
whereas in piroxicam group it was only 0.47. The
mean change in BI score was 7.9 (95%CI 0.82–5.98)
in the prednisolone group, and 4.5 in the piroxicam
group.
Discussion: In this patient group, prednisolone
resulted in significant improvement in the symptoms
and signs of CRPSI following stroke, compared to
piroxicam. Both drugs produced an improvement in
the BI score.
Introduction
Complex regional pain syndrome (CRPS) is a
relatively recent terminology coined for the
syndrome formerly known as reflex sympathetic
dystrophy, causalgia, Sudeck’s atrophy, shoulder
hand syndrome, neuroalgodystrophy and reflex
neuromuscular dystrophy. It manifests classically
persistent burning pain in a limb, with a region of
intense allodynia, hyperalgesia, extreme guarding
of the affected limb, reduced range of motion, and
objective evidence of local autonomic dysfunction
and trophic changes.1 Currently CRPS is categorized
as CRPSI when no clear nerve injury is defined,
and CRPSII when associated with clear nerve
injury.2 Stroke is an important cause of CRPSI, and
between 1.5% and 61% of patients following
stroke have been reported to develop CRPSI.3–8
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The pathophysiology of CRPS is complex, and often
occurs after a noxious event.4 During the acute
stroke when the patient is comatose, positioning
and passive physiotherapy of the patient may result
in trauma to the upper limb, including shoulder
dislocation. Presence of sensory loss, hemi-neglect
and visual inattention may result in improper
positioning, rendering the limb vulnerable to
frequent trauma, which in turn predisposes to
CRPSI. Occurrence of CRPSI is the major limiting
factor of good functional outcome, and if insufficient
attention is paid, may result in frozen shoulder, with
frequent deformity of hand and fingers. The manage-
ment of CRPSI is controversial: various pharmaco-
logical and non-pharmacological treatments have
been tried.9–12 Only two class I trials have evaluated
the role of oral corticosteroids in CRPS; both were
conducted in smaller patient populations with
heterogeneous aetiology and compared the effect
of a corticosteroid with placebo.4,13
We report the results of a randomized controlled
trial evaluating the effect of oral prednisolone over
piroxicam in patients with CRPSI following
stroke. We did not have a placebo arm, as we
included patients with moderately severe CRPS with
a score of 8 or more, in whom not offering any
treatment may not be ethical. In CRPS, swelling and
pain (spontaneous and during movement) are
dominant features and histopathology of autopsy
specimens reveals inflammatory changes.4 A role for
soluble TNF has recently been reported in the
pathogenesis of CRPS.14 Piroxicam is a potent
analgesic and anti-inflammatory drug, and is effica-
cious in several inflammatory conditions;15 it was
therefore chosen as an alternate treatment to
prednisolone.
Methods
Of 106 patients with CRPSI following stroke
managed by us from 2002 to 2004, 46 were
excluded, because of diabetes mellitus (n¼ 20),
uncontrolled hypertension (n¼ 21), ischaemic heart
disease (n¼ 6), heart failure (n¼ 2), previous history
of peptic ulcer (n¼ 5) and CRPS score 58 (n¼ 10).
We therefore studied 60 patients with CRPSI
following stroke (Figure 1). All patients gave
Assessed for eligibility
(n=106)
Excluded (n= 46)
Not meeting inclusion criteria
(n=46) due to diabetes
mellitus, uncontrolled
hypertension, ischaemic heart
disease, heart failure, previous
history of peptic ulcer and
CRPS score below 8 
Analysed (n=30)
Excluded from analysis (n=0)
Lost to follow-up (n= 0)
Discontinued intervention
(n=0) 
Allocated to prednisolone (n=30)
Received allocated intervention 
(n=30)
Did not receive allocated intervention
(n=0) 
Lost to follow-up (n= 0)
Discontinued intervention
(n=0)
Allocated to piroxicam (n=30)
Received allocated intervention
(n=30)
Did not receive allocated intervention
(n=0) 
Analysed (n=30)
Excluded from analysis (n=0)
Allocation
Analysis
Follow-Up
Enrollment
(n=60)
Randomized
Figure 1. CONSORT flowchart.
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informed consent, and the study was approved by
the local ethics committee.
Patients underwent a detailed clinical evaluation.
During the acute stage of stroke, consciousness was
assessed by Glasgow coma scale (GCS) and severity
of stroke by Canadian Neurological Scale (CNS).
The time period taken for the development of CRPSI
after stroke and onset of CRPSI to recruitment for the
trial was also noted. Activity of daily living was
assessed by the Barthel index (BI), which has a 0–20
point range, 0 being the lowest and 20 the highest.16
The diagnosis of CRPSI was based on the presence
of pain and tenderness during humeral abduction,
flexion and extension; pain and dorsal swelling over
carpal bones; moderate fusiform oedema of meta-
carpophalangeal and interphalangeal joints; change
in temperature, colour and dryness; and loss of
dorsal line and change in nails. The severity of
CRPSI was scored on a 0–14 scale (Table 1).4
Patients with a CRPS score of 58 were included
in the trial. Complete haemogram, serum chemistry,
electrocardiogram, and radiograph of chest and
shoulder joint were done. Cranial CT scan was done
within 24 h of stroke using a spiral CT scanner; 8mm
axial cuts were obtained parallel to the orbitomeatal
line. Strokes were classified into ischaemic and
haemorrhagic, and these were further categorized
according to location and size.17,18
Exclusion criteria
Patients with diabetes mellitus, uncontrolled hyper-
tension (BP 180/110mmHg), hemiplegia due to
other than stroke, history of earlier shoulder
dysfunction and deformity, rheumatoid disease,
brachial plexus injury, gastrointestinal bleeding,
septicaemia and CRPS score 58 were excluded.
Sample size calculation
Considering the improvement of therapy if CRPS
score reduced by 52, 27 patients were required in
each group for a 95% power of test, using the 5%
level of significance.
Randomization and outcome measures
Patients with CRPSI fulfilling the inclusion criteria
were randomized into study and control groups
using random table numbers. The study group
received oral prednisolone 40mg/day for 14 days,
followed by 10mg/week taper. The control
group received oral piroxicam 20mg/day. The
drugs were provided to the patients in identical
packets. Randomization was done by one investi-
gator (JK) and evaluation by another (AB). Both
the groups continued physiotherapy. The effect of
treatment was assessed at the end of 1 month. The
primary end-point was improvement in CRPS score,
with improvement considered significant if the
score was reduced by 2 or more. The secondary
end-point was improvement in Barthel Index (BI),
to obviate bias. In patients who improved com-
pletely, drugs were withdrawn; the remaining
patients were prescribed prednisolone and/or
analgesics.
Statistical analysis
Statistical analysis used SPSS software. The various
clinical and radiological parameters were compared
by non-parametric tests (2, Fisher’s exact and
Mann-Whitney U tests). To evaluate the effect of
therapy, the total CRPS score and its components
within the group were compared by Wilcoxon
signed ranked test. The effect of therapy between
the prednisolone and piroxicam groups was
compared by Mann-Whitney U test. The risk
factor was evaluated using descriptive statistics
(cross table).
Results
Of 60 patients fulfilling the inclusion criteria, 20
were female. Mean age was 56 years, range 40–70.
CRPSI symptoms developed after a median 28
Table 1 Variables used for scoring complex regional
pain syndrome I
Variable Score
Sensory: pain, hyperalgesia
No 0
Mild 1
Moderate 2
Distinct 3
Severe 4
Spontaneous 5
Autonomic: distal oedema
No 0
Mild 1
Distinct 2
Severe 3
Motoric: painless passive range of motion
Humeral abduction
4120 0
5120 1
590 2
545 3
Humeral external rotation
430 0
530 1
520 2
510 3
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(7–100) days post stroke. During the acute stage of
stroke, 59 patients had altered sensorium and four
had deep coma (GCS score 46). Mean CNS score
was 2.9; 35 patients scored 43 and 25 43.
Hemiplegia was severe (Grades 0–I) in 19 patients,
moderate (Grades II–III) in four, and mild (Grade IV)
in 20. Hemisensory loss to pin prick and joint
position was present in eight, and cortical sensory
loss in nine. CT scan revealed infarctions in 25 and
intracerebral haematoma in 35. Infarctions were
located in the middle cerebral arterial territory in 17,
anterior cerebral in six and posterior cerebral in
two patients. Haematomas were putaminal in 18,
thalamic in nine, lobar in five and infratentorial in
three patients. The size of infarcts was small in nine,
medium in 15 and large in one patient. Haemato-
mas were large in eight, medium in 20 and small in
seven. Mean BI score was 2.06 (0–20) and CRPS
score 10.3 (8–14). Baseline clinical, radiological
and CRPS parameters were not significantly different
between the prednisolone and piroxicam groups
(Table 2).
Effect of therapy
Following therapy, improvement in CRPS was
observed in 25 (83.3%) patients in the prednisolone
group, but 5 (16.7%) in the piroxicam group. In the
prednisolone group, mean CRPS score reduced
from 10.731.95 to 4.272.83 at the end of the
1 month (Z¼4.47; p5 0.0001). In the piroxicam
group, however, CRPS score reduced from
9.83 2.34 to 9.37 2.89, which is not significant
(Z¼1.64, p¼0.24).
The response to prednisolone was observed in
all the components of the CRPS scale; i.e. sensory
(Z¼4.33, p5 0.0001), autonomic (Z¼4.26,
p5 0.0001) and motor functions (humeral abduc-
tion Z¼3.96, p5 0.0001; humeral external
rotation Z¼4.34, p5 0.0001). In the piroxicam
group, a significant response was seen in autonomic
(Z¼2.50, p¼ 0.01) but not in sensory (Z¼1.31,
p¼0.19) or motor (humeral abduction Z¼0.82,
p¼0.41; humeral external rotation Z¼ 0.00, p¼
1.00) functions. Barthel index score, however,
improved in both prednisolone (Z¼4.48,
p5 0.0001) and piroxicam (Z¼4.21, p5
0.0001) groups (Table 3).
Comparing the response to therapy between
prednisolone and piroxicam groups at 1 month
revealed significant improvement in the study
group, both in total CRPS score (Z¼5.09,
p5 0.0001) and in its various components (sensory
Z¼5.43, p5 0.0001; autonomic Z¼4.32,
p5 0.0001; humeral abduction Z¼2.72, p5
0.006; humeral external rotation Z¼3.56,
p5 0.0001). BI score was also higher, although
not significantly so, in the prednisolone vs. the
piroxicam group (Z¼1.88, p¼ 0.06) (Table 4).
Considering the criterion of 2 or more points
improvement in CRPS score, 25 (83.3%) patients
showed improvement in the prednisolone and
5 (16.7%) patients in the piroxicam group, giving
an odds ratio for prednisolone therapy of 25 (95%CI
6.43–97.2).
Severity of stroke (p¼ 1.00) and BI score
(p¼ 0.25) at baseline were not related to response
to therapy. Of the 35 patients with CNS score43.5,
17 improved, and of the 25 patients with CNS score
43.5, 12 improved. Similarly, 11/17 patients with
BI score40 improved and 19/43 with BI score of 0.
None of the patients deteriorated in the predniso-
lone group but four of the piroxicam group had a
deterioration in CRPS score (mean 3.3, range 1–8).
Mild side-effects in the form of gastritis were seen
in four patients in the prednisolone and one in the
piroxicam group, and one patient in each group
developed upper respiratory tract infection. In none
of these patients, however, did drugs need to be
Table 2 Comparison of various clinical and radiological
variables in patients with CRPSI following stroke between
prednisolone and piroxicam groups
Variable Prednisolone Piroxicam
Gender
Male 20 20
Female 10 10
Stroke
Infarct 13 12
Haematoma 17 18
Haematoma size
Small 2 6
Medium 10 10
Large 5 2
Infarct size
Small 5 4
Medium 8 7
Large 0 1
Primary sensory loss
Present 2 6
Absent 28 24
Cortical sensory loss
Present 5 4
Absent 25 26
BI score mean SD 1.97 4.94 2.57 4.32
CNS score mean SD 3.07 1.77 2.53 1.44
Side-effects
None 25 28
Present 5 2
CRPS score mean SD 10.73 1.95 9.83 2.34
BI, Barthel index; CNS, Canadian neurological scale;
CRPS, complex regional pain syndrome.
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discontinued. The occurrence of side-effects was
not significantly different between the two groups
(p¼ 0.39).
Discussion
In this randomized controlled trial, improvement in
the symptoms and signs of CRPSI following stroke
was observed in 83.3% patients in the prednisolone
group, but in only 16.7% of the piroxicam group.
Benefits from corticosteroid in complex regional
pain syndrome have previously been reported in
two class I trials.4 In one study, 23 patients were
randomly allocated to oral prednisolone 10mg
three times daily or placebo, and medication was
continued until clinical remission or up to 12 weeks.
All the patients receiving prednisolone therapy
improved, but only 20% of those on placebo.13
In another study on CRPSI following stroke,
methylprednisolone 32mg/day in four divided
doses was given for 2 weeks, followed by a tapered
dose over 2 weeks, showing improvement in
symptoms in 91% of patients.4
We used a fixed protocol of single-dose oral
prednisolone in a homogenous and relatively
larger group of patients, and compared it with
piroxicam, a non-steroidal anti-inflammatory drug.
The chief limitation of our study is the lack of a
placebo control group, making it difficult to
Table 3 Primary and secondary outcome of patients with complex regional pain syndrome (CRPS) following stroke
receiving prednisolone and piroxicam
Parameters Initial (mean SD) 1 month (mean SD) Z
Prednisolone group
Total CRPS score 10.73 1.95 4.27 2.83 4.47**
Sensory 3.97 0.85 1.13 1.31 4.33**
Autonomic 2.17 0.70 0.77 0.73 4.26**
Humeral abduction 2.30 0.70 1.27 0.87 3.96**
Humeral ext rotation 2.37 0.72 1.13 0.94 4.34**
BI score 1.97 4.94 9.87 4.43 4.48**
Piroxicam group
Total CRPS score 9.83 2.34 9.37 2.89 1.16
Sensory 4.00 0.87 3.67 1.35 1.31
Autonomic 2.00 0.53 1.70 0.65 2.50*
Humeral abduction 2.03 0.85 1.97 0.93 0.82
Humeral ext rotation 2.07 0.87 2.07 0.91 0.00
BI score 2.57 4.32 7.07 5.56 4.21**
*p5 0.01; **p5 0.0001; BI, Barthel index; ext, external.
Table 4 Comparison of complex regional pain syndrome (CRPS) and Barthel Index (BI) score between prednisolone and
piroxicam groups at 1 month
Treatment n Mean rank Sum of ranks Z p
CRPS total score Prednisolone 30 19.07 572.00 5.09 50.0001
Piroxicam 30 41.93 1258.00
Components of CRPS score
Sensory Prednisolone 30 18.50 555.00 5.43 50.0001
Piroxicam 30 42.50 1275.00
Autonomic Prednisolone 30 21.35 640.50 4.32 50.0001
Piroxicam 30 39.65 1189.50
Humeral abduction Prednisolone 30 24.63 739.00 2.72 0.006
Piroxicam 30 36.37 1091.00
Humeral ext rotation Prednisolone 30 22.97 689.00 3.56 50.0001
Piroxicam 30 38.03 1141.00
BI score Prednisolone 30 34.70 1041.00 1.88 0.06
Piroxicam 30 26.30 789.00
ext, external. p values are by Mann–Whitney U test.
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assess fully the significance of the improvement with
either prednisolone or piroxicam. A placebo arm
was considered unethical, as we have included
relatively severe CRPS patients with a score of 8 or
more.
Autopsy study of CRPS reveals evidences of
perivenous micro-bleeding in the periarticular soft
tissues in the affected shoulder joints, which is more
prominent in the suprahumeral area. Perivascular
lymphocytic infiltration in the synovium and gran-
ulation tissues are also seen.4 Significant reduction
in distal swelling following piroxicam may be due
to its anti-inflammatory mechanism, as it inhibits
arachidonic acid, resulting in reduced pro-
inflammatory substances. The pain and motor
function symptoms, however, are not relieved by
piroxicam, suggesting that these symptoms in CRPS
may be due to some other additional mechanisms.
Suprahumeral structures are highly innervated
with autonomic and sensory nerve fibres.19 These
nerve endings may be injured during upward gliding
of the head of the humerus during abduction.20,21
In stroke patients, this injury is likely to be due to
severe hemiplegia, spasticity, sensory deficit and
physiotherapy.22–25 Damage to peripheral nerves
and tissues releases various chemical mediators,
and the resulting continuous stimulation of
A-delta and polymodal C fibres produces initially
localized sharp, followed by continuous, pain.26
The nociceptor barrage may alter the dorsal horn
cell processing mechanisms, allowing for the
expression of the A beta mechanoallodynia and
triggering aberrant noradrenergic sprouting within
the dorsal root ganglia.27 Corticosteroids not only
inhibit arachidonic acid metabolism resulting in
reduced production of leukotrines but also inhibit
substance P, CGRP, and regulates neuropeptides in
sensory neurons of dorsal root ganglia.13,25 The lack
of benefit from piroxicam to the sensory and motor
components suggest a dominant neural mechanism
in the pathophysiology of CRPSI. In a stroke patient,
pain in the affected side may also be due to
deafferentation of spinothalamic projection neurons,
which is characterized by hyperpathia and burning
or deep boring pain, and usually follows a small
thalamic stroke. This is unlikely in our patients,
as pain was predominantly restricted around the
shoulder joint, with limitation of movement due
to pain and associated autonomic dysfunction.
Moreover we have followed a stringent diagnostic
definition of CRPS.1,2
In our study, none of the patients developed
uncontrolled hypertension or diabetes mellitus,
and all complied with the treatment, which may
be due to a relatively small single morning dose
for shorter duration, and stringent exclusion criteria.
Gastrointestinal upsets and respiratory infections
were comparable between the two groups, and
none had to discontinue therapy due to side-effects.
In an earlier study on CRPS, following oral methyl
prednisolone therapy for similar duration, minor
side-effects were reported, including transient
increase in blood sugar in 15, sleeping problems
in 7, acne in 5 and slight increase in blood pressure
in two out of 34 patients.4
Bias was unlikely in our study, as randomization
and evaluation were done by different individuals.
Both the groups were given identical packets of drug
and advised to take one after breakfast. Although the
size and shape of the tablets were different, as the
patients were only given one modality of treatment,
this factor is unlikely to influence our results. Several
other drugs have been tried in CRPS, but the results
were no closer to corticosteroid.28
The change in BI scores was also higher in
prednisolone group than in the piroxicam group.
This may be due to the contribution of shoulder joint
functions in performing various activities of daily
living. None of our patient had fixed deformities
of fingers and shoulder joint that limited joint
function.
In conclusion, a short course of oral prednisolone
significantly reduces the symptoms and signs of
CRPSI following stroke compared to piroxicam, and
both drugs improve the activity of daily living as
assessed by BI score.
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